These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 18481809)

  • 1. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies.
    Vermorken JB; Herbst RS; Leon X; Amellal N; Baselga J
    Cancer; 2008 Jun; 112(12):2710-9. PubMed ID: 18481809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck.
    Bernier J
    Nat Clin Pract Oncol; 2008 Dec; 5(12):705-13. PubMed ID: 18825142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.
    Baselga J; Trigo JM; Bourhis J; Tortochaux J; Cortés-Funes H; Hitt R; Gascón P; Amellal N; Harstrick A; Eckardt A
    J Clin Oncol; 2005 Aug; 23(24):5568-77. PubMed ID: 16009950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
    Herbst RS; Arquette M; Shin DM; Dicke K; Vokes EE; Azarnia N; Hong WK; Kies MS
    J Clin Oncol; 2005 Aug; 23(24):5578-87. PubMed ID: 16009949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.
    Vermorken JB; Trigo J; Hitt R; Koralewski P; Diaz-Rubio E; Rolland F; Knecht R; Amellal N; Schueler A; Baselga J
    J Clin Oncol; 2007 Jun; 25(16):2171-7. PubMed ID: 17538161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Bourhis J; Rivera F; Mesia R; Awada A; Geoffrois L; Borel C; Humblet Y; Lopez-Pousa A; Hitt R; Vega Villegas ME; Duck L; Rosine D; Amellal N; Schueler A; Harstrick A
    J Clin Oncol; 2006 Jun; 24(18):2866-72. PubMed ID: 16717293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Greenhalgh J; Bagust A; Boland A; Fleeman N; McLeod C; Dundar Y; Proudlove C; Shaw R
    Health Technol Assess; 2009 Oct; 13 Suppl 3():49-54. PubMed ID: 19846029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palliative weekly chemotherapy along with cetuximab in recurrent and metastatic head and neck cancers: a retrospective analysis.
    Rangaraju RR; Sharma JB; Dewan AK; Anand AK; Sheh R; Jena A; Chaturvedi AK
    Indian J Cancer; 2012; 49(1):1-5. PubMed ID: 22842160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma.
    Péron J; Ceruse P; Lavergne E; Buiret G; Pham BN; Chabaud S; Favier B; Girodet D; Zrounba P; Ramade A; Fayette J
    Anticancer Drugs; 2012 Oct; 23(9):996-1001. PubMed ID: 22643048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck.
    Vermorken JB; Licitra L; Stöhlmacher-Williams J; Dietz A; Lopez-Picazo JM; Hamid O; Hossain AM; Chang SC; Gauler TC
    Eur J Cancer; 2013 Sep; 49(13):2877-83. PubMed ID: 23726971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of cetuximab in combination with docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after platinum-containing therapy: a multicenter study of the Arbeitsgemeinschaft Internistische Onkologie.
    Knoedler M; Gauler TC; Gruenwald V; Matzdorff A; Schroeder M; Dietz A; Jordan WO; Arnold D; Hennemann B; Hofele C; Weissinger F; Eberhardt W; Keilholz U
    Oncology; 2013; 84(5):284-9. PubMed ID: 23445718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.
    Rivera F; García-Castaño A; Vega N; Vega-Villegas ME; Gutiérrez-Sanz L
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1421-8. PubMed ID: 19828002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetuximab-Carboplatin-5-Fluorouracil Regimen in Elderly Patients with Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A French Retrospective Survey.
    Burgy M; Barthélémy P; Lefevre F; Dupret-Bories A; Truntzer P; Korenbaum C; Flesch H; Bronner G; Borel C
    Oncology; 2017; 93(1):11-17. PubMed ID: 28423384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma.
    Chan AT; Hsu MM; Goh BC; Hui EP; Liu TW; Millward MJ; Hong RL; Whang-Peng J; Ma BB; To KF; Mueser M; Amellal N; Lin X; Chang AY
    J Clin Oncol; 2005 May; 23(15):3568-76. PubMed ID: 15809453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel is effective in relapsed head and neck squamous cell carcinoma: a retrospective study of 66 patients at a single institution.
    Fayette J; Montella A; Chabaud S; Bachelot T; Pommier P; Girodet D; Racadot S; Montbarbon X; Favier B; Zrounba P
    Anticancer Drugs; 2010 Jun; 21(5):553-8. PubMed ID: 20220515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: final results of a randomized, double-blind, placebo-controlled, phase 3 study.
    Urba S; van Herpen CM; Sahoo TP; Shin DM; Licitra L; Mezei K; Reuter C; Hitt R; Russo F; Chang SC; Hossain AM; Frimodt-Moller B; Koustenis A; Hong RL
    Cancer; 2012 Oct; 118(19):4694-705. PubMed ID: 22434360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S-1 monotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck after progression on platinum-based chemotherapy.
    Yokota T; Onozawa Y; Boku N; Hamauchi S; Tsushima T; Taniguchi H; Todaka A; Machida N; Yamazaki K; Fukutomi A; Yasui H
    Jpn J Clin Oncol; 2011 Dec; 41(12):1351-7. PubMed ID: 21980053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck.
    Hussain M; Gadgeel S; Kucuk O; Du W; Salwen W; Ensley J
    Cancer; 1999 Dec; 86(11):2364-9. PubMed ID: 10590379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.
    Kiyota N; Tahara M; Kadowaki S; Fuse N; Doi T; Minami H; Ohtsu A
    Jpn J Clin Oncol; 2009 Apr; 39(4):225-30. PubMed ID: 19211574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cetuximab in the treatment of head and neck cancer.
    Bernier J
    Expert Rev Anticancer Ther; 2006 Nov; 6(11):1539-52. PubMed ID: 17134359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.